Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28380734 | 0.87 | KDM4E (0.54) | TDP2SMYD3GAAHTTKDM4E | |
| SCHEMBL29713338 | 0.86 | TDP2 (0.66) | TDP2SMYD3AHRGAAHTT | |
| SCHEMBL398818 | 0.86 | TDP2 (0.66) | TDP2SMYD3AHRGAAHTT | |
| SCHEMBL939611 | 0.84 | SMYD3 (0.59) | TDP2SMYD3HTTHDAC3KDM4E | |
| SCHEMBL29995492 | 0.84 | SMYD3 (0.59) | TDP2SMYD3HTTHDAC3KDM4E | |
| SCHEMBL688076 | 0.84 | EPHX2 (0.56) | SMYD3AHRGAAEPHX2HDAC3 | |
| SCHEMBL29567045 | 0.84 | SMYD3 (0.57) | TDP2SMYD3AHREPHX2HDAC3 | |
| SCHEMBL3190474 | 0.84 | SMYD3 (0.57) | TDP2SMYD3AHREPHX2HDAC3 | |
| SCHEMBL31518440 | 0.84 | HTT (0.57) | TDP2SMYD3GAAHTTKDM4E | |
| SCHEMBL3255662 | 0.83 | SMYD3 (0.53) | TDP2SMYD3AHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118901-A | Oxindole derivative, preparation method thereof and application thereof in TRPA1 inhibitor direction | 中国人民解放军北部战区总医院 | 2024-12-13 | — | — | CN | claimed |
| JP-2002540096-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | claimed |
| CN-1038640-A | Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-10 | — | — | CN | claimed |
| EP-0344634-A1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | claimed |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4574153-A2 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2025-05-08 | — | — | US | disclosed |
| US-20250130221-A1 | METHOD OF IDENTIFYING AGENTS FOR THE TREATMENT OF CYSTIC FIBROSIS CAUSED BY THE MUTATION F508DEL | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064829-A1 | A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-1998007695-A1 | INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | disclosed |
| US-5019587-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-28 | — | — | US | disclosed |
| EP-0168003-B1 | OXINDOL COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0344634-A1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | disclosed |
| US-4737501-A | Substituted piperazinyl oxindol compounds and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-12 | — | — | US | disclosed |
| EP-0168003-A1 | Oxindol compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | TDP2 3600/4885SMYD3 2889/4885AHR 1880/4885 |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | MAP3K20, MAP4K2, MAP4K1 | TDP2 615/4885SMYD3 3085/4885AHR 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.